secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEUROCRINE BIOSCIENCES INC (NBIX)
CIK:        0000914475
Form:       8-K
Filed at:   2024-11-01T23:59:59+00:00
Accession:  0000914475-24-000214
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Neurocrine Biosciences launches $300M accelerated share repurchase with Goldman Sachs
--------------------------------------------------------------------------------

- Entered into ASR agreement with Goldman Sachs & Co. to repurchase $300M of common stock.
- On Nov 4, 2024, will pay $300M and receive 80% of shares based on Oct 31 closing price.
- Final settlement expected in Q1 2025; additional shares or cash adjustments possible per terms.
- Repurchase conducted under previously announced $300M board-authorized share repurchase program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/914475/000091447524000214/0000914475-24-000214-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/914475/000091447524000214/nbix-20241031.htm
  HTML page:      https://secwatch.observer/filing/0000914475-24-000214

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer